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Summary. Aclarubicin is an anthracycline antibiotic that 
differs from doxorubicin in its structure, mechanism of 
action, and preclinical toxicity profile, especially its re- 
duced cardiotoxicity. We therefore conducted a side-by- 
side in vivo and in vitro trial of this agent in metastatic 
breast-cancer patients and their biopsied tumor specimens, 
respectively. Aclarubicin (100 mg/m2) was given by in- 
travenous infusion every 3 weeks to 22 patients with ob- 
jectively measurable metastatic breast cancer, 15 of whom 
had not previously received doxorubicin. The dose-limit- 
ing toxicity consisted primarily of leukopenia and severe 
nausea and vomiting. No objective response was observed 
in the 19 evaluable patients. After disease progression, 10 
of the 15 doxorubicin-naive patients were treated with 
doxorubicin; 6 patients achieved a partial response, includ- 
ing 4 who responded to doxorubicin alone and 2 who 
responded to doxorubicin in combination with thiotepa and 
vinblastine. Tumor specimens were obtained from 14 of 
the 22 patients prior to the start of therapy and were tested 
for in vitro sensitivity to aclarubicin and doxorubicin using 
a soft agar colony-forming assay, Adequate colony growth 
occurred in 9 of 14 cultured tumor specimens. All 9 speci- 
mens, including 3 obtained from doxorubicin-naive 
patients, demonstrated in vitro resistance to aclarubicin. In 
all, 1 of 3 specimens l:aken from doxorubicin-naive patients 
demonstrated in vitro sensitivity to doxorubicin, whereas 6 
tumor specimens obtained from patients who had under- 
gone prior doxorubicin therapy demonstrated in vitro resis- 
tance. The patient whose tumor demonstrated in vitro 
doxorubicin sensitivity responded to a doxorubicin regi- 
men after failing aclarubicin treatment; in vitro doxorubi- 
cin resistance correlated with clinical resistance in all 
cases. We conclude that aclarubicin is inactive in metastat- 
ic breast cancer at the dose and schedule used. Side-by-side 
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in vivo and in vitro trials are feasible and could be useful in 
the development of investigational agents with activity 
greater than that of aclarubicin and, particularly, in the 
evaluation of analogs of clinically active drugs. 
Introduction 
Anthracycline antibiotics are among the most useful of the 
currently available anticancer agents [12]. Interest in 
aclarubicin (aclacinomycin-A; ACM-A) stems from its 
class similarity, structural and mechanistic differences, and 
diminished preclinical cardiotoxicity profile as compared 
with doxorubicin [2-4]. Phase I trials established 
100 rag/m2 as a suitable dose for phase II trials using an 
every-3-week schedule, the side effects being dose-limit- 
ing myelosuppression and occasional mild hepatic toxicity 
[8]. Phase II trials in most solid tumors have been disap- 
pointing, including two studies in patients with metastatic 
breast cancer [5-6]. However, in the study by Forastiere et 
al. [5] in which no objective responses were observed, all 
22 evaluable patients with breast cancer had previously 
received doxorubicin and may therefore have been "an- 
thracycline-resistant." Although all patients were doxoru- 
bicin-naive in the negative study by Gockerman et al. [6], 
most patients were treated on a weekly schedule and the 
subsequent response or lack of response to doxorubicin or 
other agents was not reported. 
Our study was designed to evaluate the activity of 
aclarubicin given on an every-3-week schedule to patients 
with metastatic breast cancer and to cross nonresponding 
doxorubicin-naive patients over to doxorubicin treatment 
so as to obtain direct data regarding cross-resistance. 
Furthermore, the in vitro sensitivity to aclarubicin and 
doxorubicin of tumor specimens obtained from patients 
entered into this clinical trial was evaluated using a modifi- 
cation of the Hamburger-Salmon human tumor colony- 
forming assay. 
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Patients and methods Table 1. Patient's characteristics 
Clinical trial A total of 22 patients with objectively measurable meta- 
static breast cancer gave signed informed consent and were entered in the 
study. Adequate marrow reserve (WBC >4,000/mm3; granulocytes 
>2,000/ram3; platelets >150,000/mm3), renal function (serum creati- 
nine <2.0 rag/100 IN), hepatobiliary function (serum bilimbin, 
<2.0 mg/100 ml) and Kamofsky performance status (_>60%) were pre- 
sent in all patients. Sites of metastases among the patients varied, and 
most had received prior anticancer therapy (Table 1). In all, 15 patients 
had not previously received doxorubicin or other anthracycline therapy. 
Aclarubicin was given at a dose of 100 mg/m 2 intravenously over 
30 rain at 3-week intervals. Dose adjustments were made on the basis of 
hematologic toxicity. Doxorubicin-naive patients who continued to meet 
the study criteria were given doxorubicin after they had developed dis- 
ease progression during aclarubicin therapy and were followed for re- 
sponse and assessment of cross-resistance. Single-agent doxombicin 
therapy was planned, but combination drug treatment was permitted if 
rapid disease progression threatened the patients' survival. Patients were 
considered to be evaluable for response if they received two courses of 
therapy or if unequivocal disease progression could be documented. 
Standard response criteria defined in previous trials were used [7]. All 
patients were considered to be evaluable for toxicity if they completed a 
course of treatment. 
In vitro trial. After informed consent had been obtained, tissues contain- 
ing tumor cells were collected from all patients entered in the clinical trial 
with easily biopsied metastatic sites. Tumor samples were mechanically 
disaggregated into 2- to 3-mm fragments in Roswell Park Memorial 
Institute (RPMI) media containing 10% heat-inactivated fetal bovine 
serum (FBS), and malignant effusions or bone-marrow aspiration speci- 
mens were collected by centrifugation, fractionated over a Ficoll-Hy- 
paque gradient, and resnspended in media. The resulting cell suspensions 
were filtered through a sterile wire screen to remove large fragments, 
washed twice in RPMI with 10% FBS, and passed through a 25-gin 
nylon filter to remove all but single ceils. Cell viability was assessed 
using trypan blue dye exclusion, and only viable cells were used to 
determine the final concentration of plated cells. 
In vitro drug testing. Tumor cell suspensions were transferred to tubes 
prior to culture and adjusted to an appropriate final cell concentration in 
the presence of various concentrations of aclarubicin, doxorubicin, or 
media (control). Each drug was tested at three dose levels corresponding 
to final concentrations of 10, 1.0, and 0.1 gg/ml. If the cell yield was too 
low for testing of all three drug concentrations, the highest concentra- 
tions of doxorubicin and aclambicin were excluded. Following a 1-h 
exposure to media (control) or drug, cells were washed three times and 
seeded in agar cultures as described below. 
Culture procedures. Cells were suspended in 0.3% agar in RPMI con- 
taining 15% heat-inactivated FBS, transferrin (10 gg/ml), insulin 
(20 gg/ml), sodium selenite (50 nM), L-glutamine (2 rnM), and 1% (v/v) 
penicillin/streptomycin to achieve a final concentration of 5 • 105 
cells/ml • 3 - 4  ml. A l-ml aliquot of this solution was pipetted over each 
of 3 - 4  petri dishes containing 1 ml 0.5% agar in RPMI containing 15% 
FBS, L-glutamine (2 raM), and 1% (v/v) penicillin/streptomycin. The 
plates were incubated in a humidified incubator in an atmosphere con- 
taining 7.5% CO2 and were examined under an inverted microscope 
every other day beginning on day 9 for colony formation. Two extra 
"control" plates were prepared: one containing 10 gg abrin/ml in the 
bottom agar layer was incubated [10], and one fixed with glutaraldehyde 
was refrigerated. The glutaraldehyde control plate had to have less than 5 
"colonies" per plate for an experiment to be considered acceptable. If 
adequate colony growth occurred in a standard control plate (an average 
of t> 30 colonies in control plates over any background colonies seen on 
the fixed control plates) and <5 colonies grew in the abrin plate, all plates 
were counted. Colony growth in drug-exposed plates was compared with 
that in control plates. Based on the pharmacokinetics of aclarubicin and 
previous in vitro-in vivo correlative trials [1, 9, 11], in vitro sensitivity 
was defined as a concentration-dependent decrease in colony formation 
corresponding to <30% colony survival at the 0.1 btg/ml concentration 
and <5% survival at the 1.0- or 10-gg/ml concentration. 
Total number of patients on study 22 
Evalnable for response 19 
Evaluable for toxicity 20 
Median age (range) 59 (30-77) years 
Median Karnofsky performance status 
(range) 80 (60-100) 
Prior therapy: 
Chemotherapy 21 
Median number of drugs (range) 4 (0-8) 
Doxorubicin 7 
Radiotherapy 13 
Hormonal therapy 5 
Sites of measureable diseasea: 
Skin 11 
Lung 10 
Lymph node(s) 5 
Liver 5 
Toxicity: 
Drug-related deaths 0 
Hematologic: 
WBC median (lst cycle) 2.5 (0.9-5.1) • 103/mm 3 
Platelet median (1 st cycle) 136 (26 - 396) x 103/mm 3 
Gastrointestinal 
Nausea/vomiting 
(lst cycle median) grade 3 b 
a 8 Patients had 2 or mores sites of measurable disease 
b According to Southwest Oncology Group criteria 
Results 
In  all, 21 o f  22 pat ients  were  eva luab le  for toxici ty  and  19 
were  eva luab l e  for response .  The  3 u n e v a l u a b l e  pat ients  
i n c l u d e d  1 who  died  wi th in  7 days  of  the start  o f  therapy 
and  pr ior  to eva lua t ion  and  2 others  who  re fused  fur ther  
t r ea tmen t  or fo l l ow-up  after the first cycle.  Tox ic i ty  was 
subs tan t ia l  at the dose  and  schedule  e m p l o y e d  for this 
s tudy (Table  1). The  m e d i a n  W B C  nadi r  for the first cycle  
was  2 ,500 /mm3,  and  the m e d i a n  n a u s e a  and  v o m i t i n g  score  
was grade  3 (Sou thwes t  O n c o l o g y  G r o u p  cri teria)  despi te  
the use  o f  aggress ive  an t i eme t i c  r eg imens ,  i n c l u d i n g  com-  
b i n a t i o n  me toc lop ramide ,  d i p h e n h y d r a m i n e ,  lo razepam,  
and  dexamethasone .  The  pa t ien t s '  accep tance  of  this agen t  
was poor,  wi th  2 pat ients  re fus ing  fur ther  therapy with 
ac la rub ic in  after the first dose  and 3 re fus ing  all fur ther  
c h e m o t h e r a p y  for d isease  p rogress ion  du r ing  this s tudy 
because  of  severe  (grade 4) gas t ro in tes t ina l  toxici ty.  
No  ob jec t ive  r e sponse  was  obse rved  in  the 19 eva luab l e  
pa t ients  (predic ted  t rue re sponse  rate,  <15%,  P = 0.05),  
i nc lud ing  12 d o x o r u b i c i n - n a i v e  pa t ients  (predic ted  true re- 
sponse  rate, <22%,  P = 0.05; see Tab le  2). In  all, 10 of  12 
d o x o r u b i c i n - n a i v e  pat ients  were  subsequen t ly  t reated wi th  
doxorub ic in  a lone  or in  combina t i on ;  4 of  7 pat ients  treated 
wi th  doxo rub i c in  a lone  (60 m g / m  2 every  3 weeks)  and  2 o f  
3 pat ients  t reated wi th  doxo rub i c in  (40 m g / m  e) in combi -  
na t ion  wi th  th io tepa  (12 m g / m  e) and  v inb la s t ine  (4 m g / m ; ;  
T A V )  every  3 weeks  ach ieved  a part ial  response .  
T u m o r  spec imens  were  ob ta ined  f rom 14 of  22 pat ients  
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Fig. 1. Colony survival of 9 breast-cancer tumor specimens following a 
1-h exposure to aclarubicin ( 0 ,  specimen from a patient who had under- 
gone prior doxorubicin treatment; ()-, specimen from a patient who had 
not previously received doxorubicin). The shaded area indicates the area 
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Fig. 2. Colony survival of  9 breast-cancer tumor specimens following a 
l -h exposure to doxorubicin (0-, specimen from a patient who had 
undergone prior doxorubicin treatment; O-, specimen from a patient who 
had not previously received doxorubicin). The shaded area indicates the 
area into which a survival curve must fall to satisfy our definition of in 
vitro sensitivity 
(6 lymph node or cutaneous metastases, 4 malignant 
pleural effusions, and 4 bone-marrow aspirations/biopsies 
of metastatic sites). Colony growth ranged from 0-147, 
and "adequate" colony growth (as defined above) occurred 
in 9 cases (median number of control colonies, 67; range, 
30-147); the malignant phenotype of colonies was con- 
firmed by examining at least 20 hematoxylin and eosin- 
stained colonies harvested by microsyringe aspiration from 
a control plate in 7 of the 9 cases. 
Figures 1 and 2 display the colony-survival curves 
generated following exposure to aclarubicin and doxorubi- 
cin, respectively. Although a concentration-dependent loss 
in colony smwival was observed in at least 5 cases, none of 
the 9 tumor specimens demonstrated sufficient in vitro 
sensitivity to aclambicin (as defined above) for prediction 
of the in vivo response. This finding correlates well with 
the negative clinical results of the study. In all, 6 tumor 
specimens obtained from patients who had developed dis- 
ease progression following prior treatment with doxorubi- 
cin demonstrated in vitro resistance to doxorubicin; 1 of 
the 3 specimens taken from doxorubicin-naive patients 
demonstrated in vitro sensitivity and 2 demonstrated in 
vitro resistance. The patient from whom the former speci- 
men was obtained achieved a 6-month partial response to a 
doxorubicin-containing regimen (TAV), whereas the latter 
2 patients failed to respond to single-agent doxorubicin. 
Discussion 
Aclarubicin given on an every-3-week schedule is inactive 
in patients with metastatic breast cancer. When we com- 
bined our findings with the results of two other trials [5, 6], 
we found no objective response among 29 patients pre- 
viously treated with doxorubicin or among 22 doxorubicin- 
naive patients. Furthermore, in our study, 6 of 10 doxoru- 
bicin-naive patients achieved major objective responses to 
doxorubicin (alone or in combination) following treatment 
with aclarubicin. This provides strong evidence of the an- 
thracycline sensitivity and the chemoresponsiveness of at 
least a portion of the patients entered in our study. 
Our effort to conduct a side-by-side in vivo and in vitro 
trial of aclarubicin and doxorubicin using a soft agar colo- 
ny-forming assay was reasonably successful in that 9 of 14 
(64%) specimens grew sufficiently well in soft agar culture 
for the determination of in vitro drug sensitivity. At least 5 
of the 9 tumor specimens demonstrated a concentration-de- 
pendent loss in colony survival following a 1-h exposure to 
aclarubicin, confirming the cytotoxic properties of this 
novel anthracycline. However, none of the specimens de- 
monstrated a loss in colony survival sufficient to satisfy 
our definition of in vitro sensitivity. That none of our 
patients showed a clinical response to aclarubicin suggests 
that the limits set by our working definition were rea- 
sonable. One patient whose tumor specimen demonstrated 
in vitro sensitivity to doxorubicin (as defined) and in vitro 
resistance to aclarubicin achieved a partial response to a 
doxorubicin-containing regimen after failing aclarubicin 
treatment. 
In this small test sample, the results of a human tumor 
colony-forming assay correlated with a lack of response to 
chemotherapy in 11 of 11 cases and with a response in 1 of 
1 case. Although these findings are not statistically mean- 
ingful, they do suggest that side-by-side in vivo and in vitro 
trials of new agents may be feasible and that this approach 
could be useful in the development of new agents and, in 
particular, in the evaluation of analogs of clinically active 
drugs. If aclarubicin had possessed greater activity, thus 
justifying the extension of this in vivo and in vitro study to 
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an additional 15-20 doxorubicin-naive patients and their 
tumor specimens, important data regarding cross-resis- 
tance could have been obtained. We recommend further 
testing of this approach for the development and clinical 
testing of new analogs. 
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